{"id":"https://openalex.org/W1995145607","doi":"https://doi.org/10.1097/coc.0b013e318216e699","title":"Where do Antiangiogenic Agents Belong in the Treatment Algorithm for Ovarian Cancer?","display_name":"Where do Antiangiogenic Agents Belong in the Treatment Algorithm for Ovarian Cancer?","publication_year":2011,"publication_date":"2011-05-06","ids":{"openalex":"https://openalex.org/W1995145607","doi":"https://doi.org/10.1097/coc.0b013e318216e699","mag":"1995145607","pmid":"https://pubmed.ncbi.nlm.nih.gov/21552100"},"language":"en","primary_location":{"id":"doi:10.1097/coc.0b013e318216e699","doi":"https://doi.org/10.1097/coc.0b013e318216e699","is_oa":false,"landing_page_url":"https://doi.org/10.1097/coc.0b013e318216e699","pdf_url":null,"source":{"id":"https://openalex.org/S130927242","display_name":"American Journal of Clinical Oncology","issn_l":"0277-3732","issn":["0277-3732","1537-453X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040266917","display_name":"Don Steven Dizon","orcid":"https://orcid.org/0000-0001-6541-9580","observed_orcids":["https://orcid.org/0000-0001-6541-9580"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]},{"id":"https://openalex.org/I4210133025","display_name":"Women & Infants Hospital of Rhode Island","ror":"https://ror.org/03z8sn326","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210133025"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Don S. Dizon","raw_affiliation_strings":["Department of Obstetrics & Gynecology and Medicine, Warren Alpert Medical School of Brown University and Women & Infants' Hospital of Rhode Island, Providence, RI","Department of Obstetrics & Gynecology and Medicine, Warren Alpert Medical School of Brown University and Women & Infants\u2019 Hospital of Rhode Island, Providence, RI","Funding: Supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). The author received no compensation related to the development of the manuscript","Reprints: Don S. Dizon, MD, FACP, The Warren Alpert Medical School of Brown University, Medical Oncology and Integrative Care, The Center for Sexuality, Intimacy, and Fertility, The Program in Women's Oncology, Women & Infants' Hospital of Rhode Island, 101 Dudley Street, Providence, RI 02905. e-mail: [email\u00a0protected]","Writing and editorial assistance was provided by Alyssa Tippens, PhD, of MedErgy, which was contracted by BIPI for these services. The author meets the criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), was fully responsible for all content and editorial decisions, and was involved at all stages of manuscript development"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Obstetrics & Gynecology and Medicine, Warren Alpert Medical School of Brown University and Women & Infants' Hospital of Rhode Island, Providence, RI","institution_ids":["https://openalex.org/I27804330","https://openalex.org/I4210133025"]},{"raw_affiliation_string":"Department of Obstetrics & Gynecology and Medicine, Warren Alpert Medical School of Brown University and Women & Infants\u2019 Hospital of Rhode Island, Providence, RI","institution_ids":["https://openalex.org/I27804330","https://openalex.org/I4210133025"]},{"raw_affiliation_string":"Funding: Supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). The author received no compensation related to the development of the manuscript","institution_ids":[]},{"raw_affiliation_string":"Reprints: Don S. Dizon, MD, FACP, The Warren Alpert Medical School of Brown University, Medical Oncology and Integrative Care, The Center for Sexuality, Intimacy, and Fertility, The Program in Women's Oncology, Women & Infants' Hospital of Rhode Island, 101 Dudley Street, Providence, RI 02905. e-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I27804330","https://openalex.org/I4210133025"]},{"raw_affiliation_string":"Writing and editorial assistance was provided by Alyssa Tippens, PhD, of MedErgy, which was contracted by BIPI for these services. The author meets the criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), was fully responsible for all content and editorial decisions, and was involved at all stages of manuscript development","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5040266917"],"corresponding_institution_ids":["https://openalex.org/I27804330","https://openalex.org/I4210133025"],"apc_list":null,"apc_paid":null,"fwci":0.0511,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.09940358,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"36","issue":"5","first_page":"519","last_page":"525"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/angiogenesis-inhibitors","display_name":"angiogenesis inhibitors","score":0.7879999876022339},{"id":"https://openalex.org/keywords/epithelial-ovarian-cancer","display_name":"epithelial ovarian cancer","score":0.9229999780654907},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.871999979019165},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.878000020980835},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.8270000219345093},{"id":"https://openalex.org/keywords/angiogenesis","display_name":"angiogenesis","score":0.9110000133514404},{"id":"https://openalex.org/keywords/treatment-algorithm","display_name":"treatment algorithm","score":0.7269999980926514},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.8820000290870667},{"id":"https://openalex.org/keywords/recurrent-ovarian-cancer","display_name":"recurrent ovarian cancer","score":0.8989999890327454},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.8500000238418579},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.824999988079071},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/cediranib","display_name":"cediranib","score":0.8040000200271606},{"id":"https://openalex.org/keywords/pazopanib","display_name":"pazopanib","score":0.9929999709129333},{"id":"https://openalex.org/keywords/nintedanib","display_name":"nintedanib","score":0.9139999747276306},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8600000143051147}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8940972089767456},{"id":"https://openalex.org/C2778439243","wikidata":"https://www.wikidata.org/wiki/Q7157043","display_name":"Pazopanib","level":4,"score":0.8876146078109741},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8552263975143433},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.8287461996078491},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6486209034919739},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.6065232753753662},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.5929101705551147},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.5258708000183105},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5119829773902893},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.5007472038269043},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.48534098267555237},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4723673462867737},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45032137632369995},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42540428042411804},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.3061833679676056},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/coc.0b013e318216e699","doi":"https://doi.org/10.1097/coc.0b013e318216e699","is_oa":false,"landing_page_url":"https://doi.org/10.1097/coc.0b013e318216e699","pdf_url":null,"source":{"id":"https://openalex.org/S130927242","display_name":"American Journal of Clinical Oncology","issn_l":"0277-3732","issn":["0277-3732","1537-453X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:21552100","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21552100","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of clinical oncology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.6899999976158142,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":52,"referenced_works":["https://openalex.org/W1520642707","https://openalex.org/W1967830128","https://openalex.org/W1970079579","https://openalex.org/W1980179446","https://openalex.org/W1984829593","https://openalex.org/W2001114848","https://openalex.org/W2001389415","https://openalex.org/W2001989538","https://openalex.org/W2003305754","https://openalex.org/W2007194438","https://openalex.org/W2013288089","https://openalex.org/W2014996434","https://openalex.org/W2015522187","https://openalex.org/W2017414151","https://openalex.org/W2018929154","https://openalex.org/W2021645028","https://openalex.org/W2023075445","https://openalex.org/W2023150273","https://openalex.org/W2023945490","https://openalex.org/W2026171286","https://openalex.org/W2027403533","https://openalex.org/W2035907385","https://openalex.org/W2040643478","https://openalex.org/W2043588093","https://openalex.org/W2044929474","https://openalex.org/W2049603065","https://openalex.org/W2049792735","https://openalex.org/W2060097114","https://openalex.org/W2067434109","https://openalex.org/W2081263829","https://openalex.org/W2088408857","https://openalex.org/W2093767005","https://openalex.org/W2096521047","https://openalex.org/W2102056525","https://openalex.org/W2105651363","https://openalex.org/W2109400578","https://openalex.org/W2112940666","https://openalex.org/W2119460414","https://openalex.org/W2130748155","https://openalex.org/W2132889339","https://openalex.org/W2148264387","https://openalex.org/W2148326226","https://openalex.org/W2154056804","https://openalex.org/W2157920585","https://openalex.org/W2158219353","https://openalex.org/W2158734599","https://openalex.org/W2159620641","https://openalex.org/W2160581690","https://openalex.org/W2273605900","https://openalex.org/W2408072298","https://openalex.org/W2412161003","https://openalex.org/W2418287256"],"related_works":["https://openalex.org/W2520645297","https://openalex.org/W2344322811","https://openalex.org/W2758123450","https://openalex.org/W2078075549","https://openalex.org/W2155970747","https://openalex.org/W2102393017","https://openalex.org/W2741070818","https://openalex.org/W1978118055","https://openalex.org/W2168758797","https://openalex.org/W3022567155"],"abstract_inverted_index":{"Although":[0],"epithelial":[1],"ovarian":[2,29,66,80,117,154,174],"cancer":[3],"responds":[4],"well":[5],"to":[6,33,46,84,94],"chemotherapy,":[7,104],"patients":[8],"presenting":[9],"with":[10,132,156],"advanced":[11],"disease":[12],"still":[13],"have":[14],"a":[15,100,106,126,170],"poor":[16],"prognosis.":[17],"The":[18,119],"clear":[19],"role":[20],"of":[21,28,36,56,69,102],"angiogenesis":[22],"in":[23,130,153,190],"the":[24,34,191],"development":[25,35],"and":[26,65,68,79,88,112,135,140,165,176],"progression":[27],"tumorigenesis":[30],"has":[31,124],"led":[32],"several":[37,148],"novel":[38],"antiangiogenic":[39,97,120],"agents;":[40],"however,":[41],"questions":[42],"remain":[43],"as":[44,99,105,113,137],"how":[45],"best":[47],"incorporate":[48],"such":[49],"agents":[50,98],"into":[51],"current":[52],"treatment":[53,107,192],"algorithms.":[54],"Searches":[55],"PubMed":[57],"(terms:":[58,76],"angiogenesis,":[59],"VEGF,":[60],"tyrosine":[61,150],"kinase":[62,151],"inhibitor,":[63],"bevacizumab":[64,123],"cancer)":[67,81],"recent":[70],"results":[71,159,181],"from":[72,182],"key":[73],"oncology":[74],"congresses":[75],"drug":[77],"names":[78],"were":[82],"performed":[83],"identify":[85],"relevant":[86],"articles":[87],"abstracts.":[89],"Clinical":[90],"trials":[91,184],"are":[92],"ongoing":[93,183],"evaluate":[95],"investigational":[96],"component":[101],"first-line":[103,133],"option":[108],"for":[109,116,147,161,173],"recurrent":[110],"disease,":[111],"maintenance":[114,138],"therapy":[115,168],"cancer.":[118],"monoclonal":[121],"antibody":[122],"demonstrated":[125],"progression-free":[127],"survival":[128],"benefit":[129],"combination":[131],"paclitaxel/carboplatin":[134],"continued":[136],"therapy,":[139],"phase":[141,157],"II":[142],"data":[143],"suggest":[144],"therapeutic":[145],"potential":[146],"multitargeted":[149],"inhibitors":[152],"cancer,":[155,175],"III":[158],"forthcoming":[160],"BIBF":[162],"1120,":[163],"cediranib,":[164],"pazopanib.":[166],"Antiangiogenic":[167],"remains":[169],"promising":[171],"strategy":[172],"it":[177],"is":[178],"hoped":[179],"that":[180],"will":[185],"inform":[186],"their":[187],"optimal":[188],"placement":[189],"paradigm.":[193]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-06-24T00:00:00"}